The UK medicines regulator MHRA has issued guidance on how drug sponsors using its Innovative Licensing and Access Pathway (ILAP) can request integrated feedback from health technology assessment (HTA) bodies in England, Scotland and Wales on their products under development to optimize approaches to patient access.
This service - available for a fee to be agreed with the sponsor - can help to systematically address market access challenges “through preparatory discussions to understand your needs and the market access insights you are looking for,” the MHRA told companies in updated